21254-04-6

Basic information

• Product Name: 1H-Pyrazole-4-carbonitrile, 5-amino-1-cyclohexyl-
• CAS NO: 21254-04-6
• Molecular Formula: C10H14N4
• Molecular Weight: 190.248
• Mol File: 21254-04-6.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: 1H-Pyrazole-4-carbonitrile, 5-amino-1-cyclohexyl-(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Pyrazole-4-carbonitrile, 5-amino-1-cyclohexyl-(21254-04-6)
• EPA Substance Registry System: 1H-Pyrazole-4-carbonitrile, 5-amino-1-cyclohexyl-(21254-04-6)

Safety Data

• Hazardous Substances Data: 21254-04-6(Hazardous Substances Data)

Usage

Derivative of pyrazole

yes

Contains nitrile-functional group

yes

Contains amino-functional group

yes

Commonly used in synthesis of organic compounds and pharmaceuticals

yes

Versatile reactivity

yes

Potential pharmacological activities

yes

Contains cyclohexyl group

yes

Imparts unique properties to the molecule

yes

Valuable building block for creating new chemical entities

yes

Potential applications in medicinal chemistry and drug discovery

yes

Subject of interest for researchers in pharmaceutical industry

yes

Upstream product

• 24214-73-1 cyclohexylhydrazine hydrochloride 
• 123-06-8 Ethoxymethylenemalononitrile 
• 108-85-0 1-bromocyclohexane 
• 16617-46-2 3-Amino-4-cyanopyrazole 

Downstream Products

• 5444-49-5 1-cyclohexylpyrazolo[3,4-d]pyrimidin-4-amine 
• 21254-07-9 5-amino-1-cyclohexyl-1H-pyrazol-4-carboxamide 

Relevant articles and documents

HETEROCYCLIC COMPOUNDS AS RET KINASE INHIBITORS

The present invention relates to compounds of Formula I that function as inhibitors of RET (rearranged during transfection) kinase enzyme activity: wherein HET, bonds a, b, c and d, X1, X2, X3, X4, R2

PYRAZOLO[3,4-D]PYRIMIDIN-4(5H)-ONE DERIVATIVES AS PDE9 INHIBITORS

A compound of the general formula (I) wherein R1 is selected from the group consisting of phenyl unsubstituted or substituted with 1 to 3 substituents selected from F, Cl, Br, I, CN, -O-C1-C3-alkyl, fluorinated -O-C1-C3-alkyl, -(CH2)mOH and 5-membered heterocyclic group with 1 or 2 heteroatoms selected from N, O and S; and 6- or 10-membered heteroaryl with 1 to 3 heteroatoms selected from O, N and S; R2 and R3 independently of each other represent H atom or straight or branched C1-C3 alkyl; R4 is selected from the group consisting of 4- to 6- membered cycloalkyl, wherein one of carbon atoms can be replaced by O atom, and which is unsubstituted or substituted with one or two halogen atoms,and straight or branched C1-C4 alkyl; Q represents a bond or C1-C3-alkylene, which can be optionally substituted by one to three C1-C3-alkyls; X is selected from the group consisting of O, NR5, and S(O)p; R5 represents H atom or C1-C3alkyl; m is 1, 2 or 3; p is 0, 1 or 2; and salts thereof, for use as a medicament, in particular for treating cognitive function disorders and neurodegenerative diseases.

Substituted pyrazolopyrimidines

The present invention is related to chemical compositions, processes for the preparation thereof and uses of the composition. Particularly, the present invention relates to compositions that include substituted heterobicyclic pyrimidines of Formula (I): wherein R1, R2, R3, R4, R5, X, W, and ring A are as defined herein; pharmaceutical compositions of substituted heterobicyclic pyrimidines of Formula (I); and their use in the treatment of chronic neurodegenerative diseases, neurotraumatic diseases, depression and/or diabetes. More particularly, the present invention relates to substituted pyrazolopyrimidines of Formula (I).